AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05788679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor lymphocytes
Description: Donor lymphocytes in patients without immune suppression
Study NCT05788679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapering of immune suppression
Description: Tapering of immune suppression in patients who are on immune suppressive drugs
Study NCT06095713 — intervention group
Intervention type: DRUG
Intervention: Pegunigalsidase-alfa
Description: Standard of care
Study NCT06153303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
Study NCT05244135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
Study NCT05244135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
Study NCT04502407 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cisplatin-based Radiation Therapy
Description: * High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~* All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment.
Study NCT04502407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Chemotherapy
Description: * High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation.
Study NCT04849559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Tradipitant Capsule
Study NCT04849559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule
Study NCT05696093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole
Description: Use of cotrimoxazole therapy for enterobacterial VAP
Study NCT05696093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard antibiotic therapy
Description: Use of standard antibiotic therapy for enterobacterial VAP
Study NCT06519045 — intervention group
Intervention type: DEVICE
Intervention: Intelligent Fingerprinting Drug Screening System
Description: The Intelligent Fingerprinting Drug Screening System utilizes a single-use, rapid, non-invasive fingerprint sweat drug screening test intended for use with the Intelligent Fingerprinting DSR-Plus fluorescence reader. The Intelligent FingerprintingTM Fingerprint Collection Kit for Laboratory Analysis (i.e. confirmation test) provides a quantitative analytical result via laboratory-based liquid chromatography/tandem mass spectrometry (LC-MS/MS). It is used to collect and measure drug mass in the full set of 10 fingerprints.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(0.1%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(0.3%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(1%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ia(3%)
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-1(0.1%)
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-1(0.3%)
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-1(1%)
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-2(0.3%)
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-2(1%)
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Study NCT04815148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH004 Ib-2(3%)
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Study NCT05749432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay181
Description: Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
Study NCT04939142 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SVd (Selinexor+Bortezomib+dexamethasone)
Description: Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
Study NCT04939142 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vd (Bortezomib+dexamethasone)
Description: Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])
Study NCT04812262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DD01
Description: The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.
Study NCT04812262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug of DD01, administered in a 1mL volume for injection
Study NCT05024110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity treamill exercise training.
Description: We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
Study NCT05024110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity treamill exercise training.
Description: We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
Study NCT06192199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2018 edition of the Guidelines for Diagnosis
Description: According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group
Study NCT05433844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reference Drug or Test Drug
Description: Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Study NCT04632498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
Study NCT05926726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
Study NCT05089500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Description: Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.
Study NCT05089500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic Band Ligation
Description: Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.
Study NCT05503381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical resection of low rectal cancer with transanal specimens
Description: According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
Study NCT05322239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: iTBS parameters. A series of 20, 10 s trains will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
Study NCT05322239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
Study NCT06175858 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CMR
Description: We will use cmr and bone scintigraphy to detect cardiac amyloidosis due t the high accuracy and reliability
Study NCT05565469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjustment of neurostimulator settings
Description: This is an interventional prospective study. After obtaining informed consent, only necessary information will be extracted through the electronic patient record. Through post-operative imaging, a level determination of the neurostimulator tip will be done. During general consultations, patients will be asked if they experienced abdominal wall stimulation after the procedure and when (YES/NO, NRS). This will include looking at the settings of the neurostimulator. And its adjustments. Furthermore, general epidemiological characteristics such as age, gender, height, weight will be extracted from the electronic patient record.~At the consultation, another active programming will take place (in accordance with clinical programming) on the tip of the electrode to check whether it provokes abdominal wall stimulation. This will also be scored YES/NO + NRS. Then the settings will be returned as they were pre-consultation.
Study NCT05789095 — intervention group
Intervention type: OTHER
Intervention: Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)
Description: Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation.
Study NCT04797845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teleconsultation
Description: Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.
Study NCT04405401 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: SABR to all oligoprogressive lesions + continuation of current systemic therapy
Study NCT04405401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
Study NCT05321979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: MBA-P01 will be injected into the Glabellar line.
Study NCT06501560 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GWAS
Description: In GWAS studies, data are collected to determine common variants in a number of individuals, either with or without a common trait (for example,. disease) across the genome, using genome wide SNP arrays.
Study NCT05100667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: altitude (3800m)
Study NCT05100667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: altitude (3800m)
Study NCT05100667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia
Description: sea level
Study NCT05100667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxia
Description: sea level
Study NCT04876300 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
Study NCT06255743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies
Description: determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients
Study NCT04793568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon gamma 1b (IMUKIN®)
Description: 100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
Study NCT04793568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Interferon gamma 1b placebo
Description: 5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
Study NCT05462600 — intervention group
Intervention type: OTHER
Intervention: Position change
Description: Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).
Study NCT05731765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Model
Description: Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
Study NCT05531669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Project
Description: PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
Study NCT05531669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLAY Project
Description: PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
Study NCT05531669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Education
Description: Each study center provides welcome course and parent guide for families with ASD children monthly.
Study NCT05531669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Education
Description: Each study center provides welcome course and parent guide for families with ASD children monthly.
Study NCT04743180 — intervention group
Intervention type: DEVICE
Intervention: LUMINOR© Paclitaxel eluting balloon
Description: Patients will be treated with the Luminor paclitaxel eluting balloon
Study NCT05583942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trascutaneous auricular vagus nerve stimulation
Description: The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
Study NCT05583942 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The device will appear to function but no electrical stimulation will be delivered.
Study NCT05731180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identify pathological and not pathological lung sounds
Description: First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
Study NCT05866055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-973
Description: Suspension for oral administration.
Study NCT05866055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.
Study NCT05866055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration.
Study NCT05866055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Syrup for oral administration.
Study NCT06515782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Description: In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD.